What is the recommended cidofovir (Vistide) dose and treatment duration for adenovirus infection?

Cidofovir Dosing and Duration for Adenovirus Infection

For adenovirus infection in immunocompromised patients, administer cidofovir 5 mg/kg IV once weekly for 2 consecutive weeks (induction), followed by 5 mg/kg IV every 2 weeks (maintenance) until the virus is undetectable from all previously involved sites, with mandatory probenecid and IV saline hydration accompanying each dose. 1

Standard Dosing Regimen

Induction Phase

• 5 mg/kg IV once weekly for 2 consecutive weeks 1, 2
• Infuse over 1 hour at a constant rate 1
• This represents the FDA-approved induction regimen for viral infections 1

Maintenance Phase

• 5 mg/kg IV every 2 weeks after completing induction 1
• Continue until 3 consecutive negative samples are documented from all previously involved sites (blood, urine, stool, or tissue) 2
• Treatment duration typically ranges from 2-8 weeks depending on viral clearance 2, 3

Alternative Modified Dosing (Emerging Evidence)

• 1 mg/kg IV three times weekly has been used successfully in pediatric populations with lower nephrotoxicity rates 4, 5
• This regimen showed only 4% nephrotoxicity versus 15% with conventional dosing 5
• Consider for patients at higher risk of renal toxicity or in pediatric lung transplant recipients 4

Mandatory Supportive Care

Probenecid Administration

• 2 grams orally 3 hours before cidofovir 1
• 1 gram at 2 hours after completion of infusion 1
• 1 gram at 8 hours after completion of infusion (total 4 grams per dose) 1
• Probenecid blocks active tubular uptake of cidofovir, reducing nephrotoxicity 6
• Administer with food to reduce nausea; consider antiemetics prophylactically 1

Hydration Protocol

• At least 1 liter of 0.9% normal saline IV infused over 1-2 hours immediately before cidofovir 1
• Second liter of saline (if tolerated) initiated at the start of or immediately after cidofovir infusion, given over 1-3 hours 1
• Adequate hydration is critical to prevent dose-dependent nephrotoxicity 6

Renal Monitoring and Dose Adjustments

Pre-Treatment Requirements

• Contraindicated if:
  • Serum creatinine >1.5 mg/dL 1
  • Calculated creatinine clearance ≤55 mL/min 1
  • Urine protein ≥100 mg/dL (≥2+ proteinuria) 1

During Treatment Monitoring

• Check serum creatinine and urine protein within 48 hours before each dose 6, 1
• Reduce dose to 3 mg/kg if serum creatinine increases 0.3-0.4 mg/dL above baseline 1
• Discontinue cidofovir if serum creatinine increases ≥0.5 mg/dL above baseline or if ≥3+ proteinuria develops 6, 1

Clinical Context and Efficacy

Target Population

• Primarily used in hematopoietic stem cell transplant recipients and other severely immunocompromised patients 2, 7, 3
• Adenovirus infection in this population carries >50% mortality without treatment 7
• Early treatment initiated upon PCR or culture detection improves outcomes 2, 3

Treatment Response

• Clinical improvement typically occurs within days of initiating cidofovir, documented by symptom resolution and declining viral loads 7
• In pediatric HSCT patients, 98% achieved complete resolution with virus becoming undetectable 2
• Survival improved to 80-81% with early cidofovir treatment versus historical mortality rates exceeding 50% 7, 3

Common Manifestations Treated

• Diarrhea/colitis (53% of cases) 2
• Hemorrhagic cystitis (12%) 2
• Pneumonitis (11%) 2
• Hepatitis 7
• Disseminated disease (14%) 2

Safety Considerations

Nephrotoxicity Profile

• Dose-dependent nephrotoxicity includes glycosuria, bicarbonaturia, phosphaturia, polyuria, and nephrogenic diabetes insipidus 6
• Recent pediatric data suggest lower nephrotoxicity rates (13-16%) than historically reported, particularly with modified dosing 8, 5
• In immunocompetent children, acute kidney injury during cidofovir was rare (1/23 patients) and often related to concurrent sepsis rather than the drug itself 8

Drug Interactions

• Discontinue nephrotoxic agents at least 7 days before starting cidofovir: aminoglycosides, amphotericin B, foscarnet, IV pentamidine, vancomycin, NSAIDs 1
• Reduce zidovudine by 50% or temporarily discontinue on days of cidofovir infusion due to probenecid interaction 1

Carcinogenicity Warning

• Cidofovir caused mammary adenocarcinomas in rats at doses as low as 0.04 times human exposure 1
• Should be considered a potential carcinogen in humans 1
• Use only when potential benefits outweigh risks, particularly in children 1

Special Populations

Pediatric Considerations

• Safety and efficacy established in pediatric HSCT and transplant recipients 2, 4
• Modified dosing (1 mg/kg three times weekly) may be preferred in children to reduce nephrotoxicity 4, 5
• Extreme caution warranted due to long-term carcinogenicity and reproductive toxicity risks 1

Pregnancy and Fertility

• Pregnancy Category C: embryotoxic in animals 1
• Women of childbearing potential should use effective contraception during and for 1 month after treatment 1
• Men should practice barrier contraception during and for 3 months after treatment 1
• Causes hypospermia and reduced testicular weight in animals 1

Common Pitfalls to Avoid

• Never omit probenecid and hydration: these are mandatory to reduce nephrotoxicity, not optional 1
• Do not use in patients with baseline renal impairment (CrCl ≤55 mL/min or proteinuria ≥2+) 1
• Monitor renal function closely: failure to check creatinine and urine protein before each dose can lead to irreversible renal damage 6, 1
• Do not continue cidofovir if creatinine rises ≥0.5 mg/dL: this threshold mandates discontinuation 1
• Ensure viral clearance before stopping: premature discontinuation may lead to relapse and disseminated disease 3